The logic behind the "Engele Net" core patent is completely invalid!

Recently, the patent review committee of the State Information Administration decided that the compound patent of the Grigg Ingham heavy-weight variety "Engele Net" was all invalid in China, and the process was all invalidated by the application of five well-known pharmaceutical companies in China.
time, the pharmaceutical industry's long-standing case of invalid patents once again set off industry discussion, then, Engele net this product is how important? How is its core compound patent invalidated? How will domestic pharmaceutical companies benefit from this? Let's talk about it.
1. Ingle Net: The world's third "Gretn net" drug "Gretnide" class of drugs, namely SGLT2 inhibitors, is one of the most important treatment categories for type 2 diabetes in recent years, and in addition to the core of the sugar reduction effect, its "heart failure", "weight loss", "kidney failure" and other benefits, in recent years has been very high attention! The main character of this domestic patent invalidity case, "Ingre net", for this kind of drug globally listed the third SGLT2 inhibitor, before the listing of Daglei net, Kagele net, followed by the listing of Iglei net, Aegle net, Togele net, rugle net.
Ingley Net's development company for Grigg Ingelheim and Lilly, in 2014 EMA and fda has approved Engele Net listing;
sales, Ingre's net global sales reached $3,354 million, according to its 2019 annual report, and it is a compound with Ingre's net composition.
2015 Grigg Ingelheim approved the listing of "Ingley Net/Hydrochloride", "Ingre Net/Ligligletin", also has a good market performance;
2. Core Patents: 5 pharmaceutical companies apply for invalidity and eventually established! First of all, the five domestic pharmaceutical companies that applied for the patent of Blinger Ingehan Englitin compound (patent number: CN20131041419.9) were Jiangsu Hausen Pharmaceutical Group Co., Ltd., Sichuan Colum Pharmaceutical Research Institute Co., Ltd., Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., Hangzhou Sino-American East China Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd.
Figure 2.1 Patent Examination Decision No. 46013 () For the invalid application evidence of five pharmaceutical companies, the patente submitted a statement of opinion and counter-evidence to the other four pharmaceutical companies, except for the late reply to the request and evidence of Jiangsu Hausen Pharmaceutical Co., Ltd.
and on the basis of the above-mentioned statements, the component considered that the facts of the case were clear enough to allow a decision to be reviewed.
And in this case, the main decision given by the d?d'a-council was that the technical solution was not creative if the difference between the technological scheme of the invention and the closest existing technology was given in the existing technology and applied to the closest existing technology to solve its technical problems.
Generally possible, if the differentiated feature is the usual means of solving the technical problems in this field, it may be considered that there is a revelation in the existing technology that the differentiated feature should be applied to the closest to the existing technology to solve its technical problems.
At the same time, it is more important to understand that, before this, the State Information Bureau 33101 invalid declaration request review, has decided that the claim 1-6 invalid, 7-9 to maintain valid, that is, "partial invalidity", and this State Information Bureau 46013 invalidity declaration, that is, on this basis, continue to request invalid, and finally set up ... To sum up, Engele net compound patents, all invalid! Figure 2.2 Patent Examination Decision No. 33101 Content ()3. All invalid: Which domestic pharmaceutical companies will benefit from this? First of all, based on the establishment of this patent invalidity case, if the parties are not convinced of this decision, they may, in accordance with the provisions of Article 46, paragraph 2, of the Patent Law, bring a suit in the Beijing Intellectual Property Court within three months from the date of receipt of this decision.
the author believes that in the face of five years of patent protection period, Grigg Ingeham will not give up the patent right.
but here, we can understand that if this patent is invalid eventually established, which domestic pharmaceutical companies will benefit from it? Domestic registration application for Engli net (also known as Ipale net), in addition to the original research Bollinger Ingham, domestic pharmaceutical companies have more than 10 declared, respectively, Jiangsu Osaikang Pharmaceuticals, Jiangsu Wanbang Biochemical Medicine, Zhengda Tianqing Pharmaceuticals, Sichuan Colum Pharmaceuticals, Jiangsu Haussen Pharmaceuticals, Nanjing Haina Pharmaceuticals, Beijing Leresen Pharmaceuticals, Chengdu Yuandong Pharmaceuticals, Jichuan Pharmaceuticals, Nanjing Warwick Pharmaceuticals, Beijing Huawokang Pharmaceuticals, Fangzheng Pharmaceutical Research Institute, Hubei Huashitong Biopharmaceuticals, Shandong Yikang Pharmaceuticals, Hong Kong Jiuhua Huayuan Group Luzhou Pharmaceuticals, Shandong Luoxin, Beijing Bo Quanjian Pharmaceuticals, Jiangsu Kefeiping Pharmaceuticals, etc.;
Further inquiries into the layout of Jiangsu Hausen and Sichuan Colum in the "Gree Net" drug found that, in addition to the above-mentioned Engele Net, Jiangsu Haussen also registered to declare Kagle Net (approved production), Dagli Net, and Sichuan Colum also registered to declare Kagli Net.
the two companies, the future competition in the "Gretn net" class of drugs is also expected.
And the patent invalid of the other 3 domestic enterprises, Jiangsu Wanbang Biopharmaceutical has been registered to declare a class 1 new drug Wangli net, Hangzhou Sino-American East China Pharmaceutical Registration declared the chemical drug 4 varieties of "metformin Engli net tablets", Zheng Tianqing also registered and declared the chemical drug 4 categories of Kagle net tablets (approved production) ... In summary, it can be seen that the five pharmaceutical companies that applied for invalid patents, as far as "Gretin" class of drugs are concerned, all have a close interest in the relationship.
summary, that is, the brief background of this Nglile net compound patent invalidity case.
domestic pharmaceutical companies in the application for two patent invalid process, the final all its compound patents invalid, for the domestic imitation paved the way for their own varieties laid the foundation.
in fact, as early as last year, Ingree net after negotiations, that is, the lowest price in the world to enter our country's health insurance, the cost of daily treatment <5 yuan, has benefited our people.
it's not hard to imagine what kind of bidding would take if the patent were invalid.
In the global heavy bomb drugs have been invalid at home today, to think is no longer for imitation species how to break the game, more to think about how to protect our own innovative varieties, otherwise, today we use the spear, will eventually evolve into someone else to break our own IP sharp weapon! Author . . Johnson References: 1. The official website of the State Administration of Information/ the official website of the Patent Review Board 2. Grigg Ingeham Official Website/Annual Report 3. FDA official website 4. EMA official website 5. CDE official website